Passage BIO, Inc. — Investor Relations & Filings
Filings indexed
414
across all filing types
Latest filing
2022-01-21
Director's Dealing
Country
US
United States of America
Listing
US
PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for central nervous system (CNS) disorders. The company develops a portfolio of adeno-associated virus (AAV)-delivered therapeutics designed to treat rare, monogenic neurodegenerative diseases by delivering functional genes to patients with mutated or nonfunctional ones. Its lead clinical program, PBFT02, is a gene therapy being evaluated in a Phase 1/2 study for the treatment of Frontotemporal Dementia (FTD) with progranulin gene (GRN) mutations. Passage Bio aims to advance its pipeline to redefine the course of neurodegenerative conditions for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Director's Dealing 2022 | 2022-01-21 | English | |
| Director's Dealing 2022 | 2022-01-14 | English | |
| 8-K | 2022-01-10 | English | |
| 8-K | 2021-12-17 | English | |
| FORM 4 SUBMISSION | 2021-12-10 | English | |
| Major Shareholding Notification 2021 | 2021-12-10 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
3 filings
| |||||
| 13204026 | Director's Dealing 2022 | 2022-01-21 | English | ||
| 13204027 | Director's Dealing 2022 | 2022-01-14 | English | ||
| 13204028 | 8-K | 2022-01-10 | English | ||
|
2021
12 filings
| |||||
| 13204029 | 8-K | 2021-12-17 | English | ||
| 13204030 | FORM 4 SUBMISSION | 2021-12-10 | English | ||
| 13204031 | Major Shareholding Notification 2021 | 2021-12-10 | English | ||
| 13204032 | 10-Q | 2021-11-04 | English | ||
| 13204033 | 8-K | 2021-11-04 | English | ||
| 13204034 | 8-K | 2021-11-01 | English | ||
| 13204035 | Major Shareholding Notification 2021 | 2021-10-25 | English | ||
| 13204036 | 8-K | 2021-10-04 | English | ||
| 13204037 | FORM 4 SUBMISSION | 2021-08-26 | English | ||
| 13204038 | FORM 3 SUBMISSION | 2021-08-26 | English | ||
| 13204039 | 10-Q | 2021-08-05 | English | ||
| 13204040 | 8-K | 2021-08-05 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Passage BIO, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34849/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34849 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34849 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34849 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34849}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Passage BIO, Inc. (id: 34849)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.